No matches
Type 2 Inflammation

AANP 2025 | Atopic Diseases & a Case-Based Panel of Nurse Practitioners

Experts from different specialties use a case-based discussion to understand type 2 inflammatory diseases from a nurse practitioner perspective.
Lakshi Aldredge
Miguel Lanz
Angela Bretton
ANP-BC, DCNP, FAANP, MSN
Lakshi Aldredge +3 more

Related resources

Type 2 Inflammation in EoE and Impact on Disease Burden

Type 2 Inflammation in EoE and Impact on Disease Burden

expert video
IRS-ISIAN 2024 | Remission in CRSwNP: A Real-World Perspective

IRS-ISIAN 2024 | Remission in CRSwNP: A Real-World Perspective

expert video
Overview of EoE Pathophysiology and the Impact on Patient Burden

Overview of EoE Pathophysiology and the Impact on Patient Burden

expert video
ERS-ISIAN 2023 | Implementation of Guidelines into Daily Practice: Past, Present, and Future

ERS-ISIAN 2023 | Implementation of Guidelines into Daily Practice: Past, Present, and Future

expert video
ESPGHAN 2024 | Burden and Timely Recognition of Pediatric EoE

ESPGHAN 2024 | Burden and Timely Recognition of Pediatric EoE

expert video
ESPGHAN 2024 | Clinical Management of Young Children With EoE

ESPGHAN 2024 | Clinical Management of Young Children With EoE

expert video
ADVENT On Air | Dysphagia in EoE: How Can You See Beyond Patients’ Adaptive Behaviors?

ADVENT On Air | Dysphagia in EoE: How Can You See Beyond Patients’ Adaptive Behaviors?

Podcast
ADVENT On Air | More Than Just Difficulty Swallowing: EoE Burden and Diagnosis

ADVENT On Air | More Than Just Difficulty Swallowing: EoE Burden and Diagnosis

Podcast
Adaptive Behaviors in EoE Infographic

Adaptive Behaviors in EoE Infographic

Infographic
Assessing EoE: Monitoring Patients With EoE in Clinical Practice

Assessing EoE: Monitoring Patients With EoE in Clinical Practice

expert video
Type 2 Inflammation Underpins Pediatric Severe Asthma

Type 2 Inflammation Underpins Pediatric Severe Asthma

Infographic
ERS-ISIAN 2023 | From Endotype to Phenotype: Linking Pathophysiology to Burden and Clinical Management for Patients with Uncontrolled and/or Severe CRSwNP

ERS-ISIAN 2023 | From Endotype to Phenotype: Linking Pathophysiology to Burden and Clinical Management for Patients with Uncontrolled and/or Severe CRSwNP

expert video
GINA-Based Opportunities for Improved Outcomes With Effective Management of Pediatric Asthma in Children 6-11 Years of Age

GINA-Based Opportunities for Improved Outcomes With Effective Management of Pediatric Asthma in Children 6-11 Years of Age

interactivity
IRS-ISIAN 2024 | Emerging Expert Definitions of Remission in CRSwNP

IRS-ISIAN 2024 | Emerging Expert Definitions of Remission in CRSwNP

expert video
IRS-ISIAN 2024 | The Underappreciated Burden of Smell Loss and Congestion in CRSwNP

IRS-ISIAN 2024 | The Underappreciated Burden of Smell Loss and Congestion in CRSwNP

expert video
IRS-ISIAN 2024 | Mechanisms of Smell Loss in CRSwNP: Blockage and Inflammation

IRS-ISIAN 2024 | Mechanisms of Smell Loss in CRSwNP: Blockage and Inflammation

expert video
ADVENT On Air | What Is the Future Outlook for Remission in Pediatric Severe Asthma?

ADVENT On Air | What Is the Future Outlook for Remission in Pediatric Severe Asthma?

Podcast
ADVENT On Air | Loss of Smell in CRSwNP Patients

ADVENT On Air | Loss of Smell in CRSwNP Patients

Podcast
ADVENT On Air | Remission in CRSwNP

ADVENT On Air | Remission in CRSwNP

Podcast
ADVENT On Air | The Road Ahead: Achieving Remission for ​Patients With Asthma

ADVENT On Air | The Road Ahead: Achieving Remission for ​Patients With Asthma

Podcast
How do You Define Active Disease (CRSwNP) When Looking at the Nose With an Endoscope?

How do You Define Active Disease (CRSwNP) When Looking at the Nose With an Endoscope?

expert video
Can Chronic Rhinosinusitis With Nasal Polyps be Considered in Remission if the Patient has an Impaired Sense of Smell?

Can Chronic Rhinosinusitis With Nasal Polyps be Considered in Remission if the Patient has an Impaired Sense of Smell?

expert video
Dr. Giorgio Canonica Regarding Multidisciplinary Approach

Dr. Giorgio Canonica Regarding Multidisciplinary Approach

expert video
Should we Still Operate on Patients With Chronic Rhinosinusitis With Nasal Polyps?

Should we Still Operate on Patients With Chronic Rhinosinusitis With Nasal Polyps?

expert video
Eosinophils as a Biomarker for Type 2 Asthma

Eosinophils as a Biomarker for Type 2 Asthma

expert video
Airway Remodeling in Type 2 Asthma is Driven by IL-4 and IL-13

Airway Remodeling in Type 2 Asthma is Driven by IL-4 and IL-13

expert video
ERS 2024 | Understanding the Complex Pathophysiology of COPD

ERS 2024 | Understanding the Complex Pathophysiology of COPD

expert video
COPD and Asthma: What's the Difference and Is There a Link?

COPD and Asthma: What's the Difference and Is There a Link?

interactivity
What Are the Key Inflammatory Processes in Patients with COPD?

What Are the Key Inflammatory Processes in Patients with COPD?

expert video
Assessing EoE: Assessing Histologic Features in EoE

Assessing EoE: Assessing Histologic Features in EoE

expert video
Assessing EoE: Measuring Quality of Life in Patients With EoE

Assessing EoE: Measuring Quality of Life in Patients With EoE

expert video
Assessing EoE: Using Endoscopic Features to Assess Disease Status

Assessing EoE: Using Endoscopic Features to Assess Disease Status

expert video
Connecting Type 2 Inflammation to CRSwNP

Connecting Type 2 Inflammation to CRSwNP

expert video
CRSwNP Significantly Affects the Quality of Life of CRSwNP Patients

CRSwNP Significantly Affects the Quality of Life of CRSwNP Patients

interactivity
Eosinophilic Esophagitis (EoE) Interactive Patient Case

Eosinophilic Esophagitis (EoE) Interactive Patient Case

interactivity
FeNO as a Biomarker for Type 2 Asthma

FeNO as a Biomarker for Type 2 Asthma

expert video
Food Bolus Impaction: An Opportunity to Diagnose EoE

Food Bolus Impaction: An Opportunity to Diagnose EoE

expert video
Gap in Care Leads to Progression of Fibrosis in EoE

Gap in Care Leads to Progression of Fibrosis in EoE

expert video
IgE as a Biomarker for Type 2 Asthma

IgE as a Biomarker for Type 2 Asthma

expert video
Importance of Early Diagnosis of Pediatric EoE

Importance of Early Diagnosis of Pediatric EoE

expert video
Interdisciplinary Care for EoE: Experts Offer Food for Thought

Interdisciplinary Care for EoE: Experts Offer Food for Thought

expert video
Interplay of Barrier Dysfunction and Type 2 Inflammation in EoE

Interplay of Barrier Dysfunction and Type 2 Inflammation in EoE

expert video
It Takes a Village: Patient-Centered Care in Pediatric EoE

It Takes a Village: Patient-Centered Care in Pediatric EoE

expert video
Keeping an Eye on Pediatric EoE

Keeping an Eye on Pediatric EoE

expert video
Managing the Risk of Fibrostenosis in EoE

Managing the Risk of Fibrostenosis in EoE

expert video
Monitoring Lung Function Is an Important Aspect of Pediatric Asthma Management

Monitoring Lung Function Is an Important Aspect of Pediatric Asthma Management

interactivity
Multifaceted Burden of Pediatric EoE

Multifaceted Burden of Pediatric EoE

expert video
On-Treatment Clinical Remission in Asthma Patients Case Tool

On-Treatment Clinical Remission in Asthma Patients Case Tool

interactivity
Patient Burden in Eosinophilic Esophagitis

Patient Burden in Eosinophilic Esophagitis

expert video
Patient Case - The Value of a Complete Pathology Report in EoE

Patient Case - The Value of a Complete Pathology Report in EoE

expert video

Learning objectives

  • Recognize common clinical signs and symptoms of type 2 inflammatory diseases seen in primary care and determine when to refer to a specialist
  • Understand the common underlying pathophysiology of type 2 inflammation in multiple atopic diseases​
  • Explore the impact of multimorbidity on patient burden and apply collaborative strategies to optimize care

Description

Lakshi Aldredge, Angela Bretton, Miguel Lanz, and Hilary Ugras use a collaborative case-based panel discussion to explore the interconnected nature of chronic underlying type 2 inflammation and its profound impact across multiple diseases and share insights that can be applied in clinical practice to optimize collaborative patient care.

Tags
type 2 inflammationsymptomsth2 polarizationquality of lifemultidisciplinary carecoexisting diseasesdiagnosispatient caseupper airwaylower airwayloss of smellitchfev1
MAT-GLB-2504896 - 1.0 - 09/2025

About these experts

Dermatology
ANP-BC, DCNP, FAANP, MSN

Lakshi Aldredge

Director for the Primary Care NP Residency Program, VA Portland Health System | Portland, OR

Allergy/Immunology
MD, FAAAAI

Miguel Lanz

Lanz Allergy, Asthma & Immunology AAADRS Clinical Research Center | Coral Gables, FL

Allergy/Immunology
APRN, FNP-BC, MSN

Angela Bretton

San Diego Allergy and Immunology | Vista, CA

Gastroenterology
FNP-BC, MSN

Hilary Ugras

Beth Israel Deaconess Medical Center | Boston, MA

ADVENT is a global medical education non-promotional program by Sanofi and Regeneron. This website is intended only for duly authenticated healthcare professionals in Algeria, Argentina, Australia, Austria, Bahrain, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Costa Rica, Croatia, Czech Republic, Denmark, Dominican Republic, Ecuador, Egypt, Estonia, Finland, France, Germany, Greece, Guatemala, Hong Kong, Hungary, Iceland, India, Israel, Italy, Japan, Kuwait, Latvia, Lebanon, Lithuania, Macau, Malaysia, Norway, Oman, Panama, Peru, Poland, Portugal, Qatar, Romania, Saudi Arabia, Singapore, Slovenia, South Africa, South Korea, Spain, Sudan, Sweden, Switzerland, Taiwan, Thailand, The Netherlands, Turkey, United Arab Emirates, or the United States of America.

For healthcare professionals in Algeria: Please read the additional Terms of Use.

Sanofi | Regeneron Logo

© 2025 Sanofi and Regeneron Pharmaceuticals, Inc.

All rights reserved.
MAT-GLB-2302957 v3.0 11/2023

All Rights Reserved.

Sanofi and Regeneron are global leaders in pharmaceutical development, each with a long history of supporting frontline physicians to improve human health and reduce the burden of disease. Driven by the same commitment to patients and their families, Sanofi and Regeneron have partnered to take on type 2 inflammation and the range of chronic conditions in which excessive inflammation plays a role.

Country/region: SpainChange country/region